Source: ERS Lung Science Conference 2021



Rating:

Share or cite this content

Citations should be made in the following way:
Sabine Behrend, Germany. PP134 – Mapping of Kras mutations during chemical carcinogenesis. ERS Lung Science Conference 2021

Member's Comments

No comment yet.

Related content which might interest you: Mapping of Kras mutations during chemical carcinogenesis Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Mapping of KRAS mutations during chemical carcinogenesis Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases Year: 2020 LSC - 2021 - Mapping of Kras mutations during chemical carcinogenesis Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Mutation of TP53 and KRAS, and loss of p16ink4a and p14arf expression in lung cancers in relation to tobacco smoke Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 Alteration patterns of tobacco carcinogens in lung adenocarcinoma reveal novel KRAS-addicted candidate oncogenes Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Are KRAS mutations druggable? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Target other gene point mutations: HER2 and rare EGFR mutations Source: ERS Research Seminar Year: 2015 KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017 Detection of k-ras codon 12 mutations in human lung tumour tissue by REMS-PCR Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Oncogenic potential of MET SEMA mutations affecting brain metastases from NSCLC is sustained by their microrheological features Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 Inhibition of hypoxia-induced phenotype alterations through epithelial-mesenchymal transition (EMT) in lung cancer by gene modulation of phosphorylation sites in tumor suppressor PTEN Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 Monoallelic germline ATM mutation and organising pneumonia induced by radiation therapy to the breast Source: Eur Respir J 2016; 47: 997-1000 Year: 2016 Genetic polymorphisms of k-ras gene in smoking related diseases Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011